Sonnet BioTherapeutics Holdings, Inc. (SONN)
Company Description
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action.
The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer.
The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer.
It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6.
The company is headquartered in Princeton, New Jersey.
Country | United States |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 12 |
CEO | Dr. Pankaj Mohan Ph.D. |
Contact Details
Address: 100 Overlook Center, Suite 102 Princeton, New Jersey 08540 United States | |
Phone | 609-375-2227 |
Website | sonnetbio.com |
Stock Details
Ticker Symbol | SONN |
Exchange | NASDAQ |
Fiscal Year | October - September |
Reporting Currency | USD |
CIK Code | 0001106838 |
CUSIP Number | 83548R105 |
ISIN Number | US83548R3030 |
Employer ID | 52-2102141 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Pankaj Mohan Ph.D. | Founder, Chairman, Chief Executive Officer and President |
Dr. John K. Cini Ph.D. | Chief Scientific Officer and Co-Founder |
Jay Cross | Chief Financial Officer |
Donald J. Griffith CPA, CPA | Controller and Director |
Susan Dexter | Chief Technical Officer |
Dr. Richard T. Kenney FACP, M.D. | Chief Medical Officer |
Manuel Dafonseca | Head of Clinical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 11, 2024 | 8-K | Current Report |
Mar 6, 2024 | 8-K | Current Report |
Feb 14, 2024 | 8-K | Current Report |
Feb 14, 2024 | 10-Q | Quarterly Report |
Feb 1, 2024 | 8-K | Current Report |
Jan 29, 2024 | 8-K | Current Report |
Jan 4, 2024 | EFFECT | Notice of Effectiveness |
Jan 2, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Dec 27, 2023 | 8-K | Current Report |
Dec 22, 2023 | S-3 | Registration statement under Securities Act of 1933 |